No Influence of Ethnic Origin on the Pharmacokinetics and Pharmacodynamics of Melagatran Following Oral Administration of Ximelagatran, a Novel Oral Direct Thrombin Inhibitor, to Healthy Male Volunteers

By Johansson L.C.   Andersson M.   Fager G.   Gustafsson D.   Eriksson U.G.  

Clinical Pharmacokinetics, Vol. 42, Iss. 5, 2003-01 ,pp. : 475-484

Adis International

Access to resources Recommend Favorite

Comparable Pharmacokinetics and Pharmacodynamics of Melagatran in Japanese and Caucasian Volunteers after Oral Administration of the Direct Thrombin Inhibitor Ximelagatran

By Wernevik Linda C.  

Clinical Pharmacokinetics, Vol. 45, Iss. 1, 2006-01 ,pp. : 85-94

Adis International

Access to resources Recommend Favorite

No Influence of Obesity on the Pharmacokinetics and Pharmacodynamics of Melagatran, the Active Form of the Oral Direct Thrombin Inhibitor Ximelagatran

By Sarich T.C.  

Clinical Pharmacokinetics, Vol. 42, Iss. 5, 2003-01 ,pp. : 485-492

Adis International

Access to resources Recommend Favorite

The direct thrombin inhibitor ximelagatran/melagatran: a systematic review on clinical applications and an evidence based assessment of risk benefit profile

By Testa Luca   Bhindi Ravinai   Agostoni Pierfrancesco   Abbate Antonio   Zoccai Guiseppe GL Biondi   van Gaal William J  

Expert Opinion on Drug Safety, Vol. 6, Iss. 4, 2007-07 ,pp. : 397-406

Informa Healthcare

Access to resources Recommend Favorite

Population Pharmacokinetics of Melagatran, the Active Form of the Oral Direct Thrombin Inhibitor Ximelagatran, in Atrial Fibrillation Patients Receiving Long-Term Anticoagulation Therapy

By Bååthe Sofie  

Clinical Pharmacokinetics, Vol. 45, Iss. 8, 2006-01 ,pp. : 803-819

Adis International

Access to resources Recommend Favorite